Mineralys Therapeutics, Inc. (MLYS) Institutional Ownership

Ownership Summary

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) currently has 4 active institutional owners and shareholders as of today (December 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• The percentage of Mineralys Therapeutics owned by institutions changed from 112.4% in September 2025 to 0.0% in December 2025, marking a slight down trend.
• On a quarter-over-quarter basis, institutional holdings shifted by 1.12%, with a year-over-year a decrease of 96.40% in the count of filers.
• During the quarter, 1 institutions bought more Mineralys Therapeutics shares, 0 sold shares, and 3 of the 4 total investors held their position steady.
• This class of investors increased its holdings in Mineralys Therapeutics to 1.36K shares for the 13F-cycle ending December 2025, up by 15 shares quarter on quarter, and down 46.51Mn shares year over year.
• As of December 31, 2025, Versant Capital Management, Inc held Mineralys Therapeutics's largest shareholding position with over 513 shares, representing 0.00% of total outstanding shares.
• Among the most significant buyers of Mineralys Therapeutics during December 2025 were GAMMA Investing LLC (15).
• The top 4 institutional holders of Mineralys Therapeutics for the quarter ending December 2025 included Versant Capital Management, Inc (513), GAMMA Investing LLC (451), MassMutual Private Wealth & Trust, FSB (319), True Wealth Design, LLC (76).